Pub Date : 2022-12-22DOI: 10.20471/lo.2022.50.02-03.15
Mirjana Mioč, G. Brozović, L. Štefančić, I. Šklebar, M. Stanec
To date, modern medicine does not have reliable tools for objectifying and measuring pain. In order to avoid the development of chronic pain, we must effectively treat intraoperative and postoperative acute pain. In this prospective study, we wanted to estimate whether and to what extent algometer and PSQ (Pain Sensitivity Questionnaire) and CSQ (Coping Strategies Questionnaire) predict the intensity and strength of postoperative pain. Accordingly, we wanted to adjust the analgesia protocol. The study was conducted from February to April 2019, at the University Hospital for Tumors in Zagreb, and included 100 patients who were admitted to the hospital for breast cancer surgery. Preoperatively all patients completed PSQ and CSQ questionnaires and pain sensitivity was measured with the algometer. The same analgesic protocol was applied to all patients. The pain was measured postoperatively by NRS (numeric rating scale) 2, 6, 12, 18, 24, 48 and 72 hours after the operation. According to the obtained results, the patients were grouped into the group of slightly sensitive, medium sensitive, or very sensitive. Correlation between PSQ and NRS was statistically significant in the group of very sensitive patients. Research has shown that algometer can identify very sensitive patients and enables planning the analgesic protocol prior the operation. We can conclude that the analgesic protocol applied during the study was successful in preventing postoperative pain.
{"title":"Predictors of acute postoperative pain in patients with breast cancer","authors":"Mirjana Mioč, G. Brozović, L. Štefančić, I. Šklebar, M. Stanec","doi":"10.20471/lo.2022.50.02-03.15","DOIUrl":"https://doi.org/10.20471/lo.2022.50.02-03.15","url":null,"abstract":"To date, modern medicine does not have reliable tools for objectifying and measuring pain. In order to avoid the development of chronic pain, we must effectively treat intraoperative and postoperative acute pain. In this prospective study, we wanted to estimate whether and to what extent algometer and PSQ (Pain Sensitivity Questionnaire) and CSQ (Coping Strategies Questionnaire) predict the intensity and strength of postoperative pain. Accordingly, we wanted to adjust the analgesia protocol. The study was conducted from February to April 2019, at the University Hospital for Tumors in Zagreb, and included 100 patients who were admitted to the hospital for breast cancer surgery. Preoperatively all patients completed PSQ and CSQ questionnaires and pain sensitivity was measured with the algometer. The same analgesic protocol was applied to all patients. The pain was measured postoperatively by NRS (numeric rating scale) 2, 6, 12, 18, 24, 48 and 72 hours after the operation. According to the obtained results, the patients were grouped into the group of slightly sensitive, medium sensitive, or very sensitive. Correlation between PSQ and NRS was statistically significant in the group of very sensitive patients. Research has shown that algometer can identify very sensitive patients and enables planning the analgesic protocol prior the operation. We can conclude that the analgesic protocol applied during the study was successful in preventing postoperative pain.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41328829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-12DOI: 10.20471/lo.2022.50.01.04
B. Petrić-Miše, Mirko Pešo, Darijo Hrepić, Vesna Telesmanić-Dobrić, E. Vrdoljak
Summary Aim: To evaluate the treatment outcomes, with emphasis on the efficacy and safety of olaparib, in patients with plati -num-sensitive, Brca-mutated, recurrent ovarian cancer treated at the University Hospital center split in the period from June 2016 to april 2021. Methods: Data were collected retrospectively from a medical history of 28 patients with platinum-sensitive, Brca-mutated, recurrent ovarian cancer. Medical records were reviewed for clinico-pathological characteristics, number of previ ous chemotherapy lines and platinum-free interval before olaparib, response to olaparib, survival outcomes (time to disease progression, time from first cycle of olaparib to the first cycle of chemotherapy for the first and second relapse / progression, overall survival) and safety. Median follow up time was 27 months. Results: all patients were Brca mutated, with a 75% predominance of Brca1 mutation. the median platinum-free interval was 13 months. Most patients were treated after the first relapse (64%) with a three-weekly TC protocol (68%). olaparib maintenance therapy provided clinical control rate in 43% of cases. the median progression free survival was 24 months. Discontinuation of olaparib treatment was reported due to disease progression in 16 patients. the median time to first subsequent chemotherapy was 31 months and time to second subsequent chemotherapy was 38 months. The tolerabil ity of olaparib was good and the side effects were low intensity. The median overall survival is not reached. Conclusion: this retrospective analysis of patients with platinum-sensitive, Brca-mutated, recurrent ovarian cancer showed that the treatment outcomes, ie efficacy and tolerability of olaparib after platinum-based chemotherapy in everyday clinical practice, are comparable to those observed in clinical trials with olaparib in the same indications. ous lines of chemotherapy, ie number of previous relapses, response to chemotherapy and plati-num-free interval before olaparib. We analyzed efficacy of olaparib treatment. Disease response to treatment was monitored by the recist (re-sponse evaluation criteria in solid tumors) sys-tem. Response to therapy is defined as a complete response (cr) or complete disappearance of the tumor, partial response (partial response - pr), stable disease (stable Disease - sD) or progression of the disease (progressive Disease - pD). overall survival (OS) is defined by the period from dis ease diagnosis to death from a tumor or from some other cause. progression-free survival (pfs) is defined as the period from the diagnosis of ovarian, fallopian tube, and peritoneal cancer to disease progression, disease recurrence, and/or patient death. TFST (Time to First Subsequent Therapy) is defined as the period from the start of olaparib treatment to the start (chemo)therapy for the first relapse/progression. TSST (Time to Sec ond Subsequent Therapy) is defined as the period from the start of olaparib treatment to the start (chemo)
{"title":"Treatment outcomes of patients with brca-mutated, recurrent ovarian cancer in University Hospital Center Split","authors":"B. Petrić-Miše, Mirko Pešo, Darijo Hrepić, Vesna Telesmanić-Dobrić, E. Vrdoljak","doi":"10.20471/lo.2022.50.01.04","DOIUrl":"https://doi.org/10.20471/lo.2022.50.01.04","url":null,"abstract":"Summary Aim: To evaluate the treatment outcomes, with emphasis on the efficacy and safety of olaparib, in patients with plati -num-sensitive, Brca-mutated, recurrent ovarian cancer treated at the University Hospital center split in the period from June 2016 to april 2021. Methods: Data were collected retrospectively from a medical history of 28 patients with platinum-sensitive, Brca-mutated, recurrent ovarian cancer. Medical records were reviewed for clinico-pathological characteristics, number of previ ous chemotherapy lines and platinum-free interval before olaparib, response to olaparib, survival outcomes (time to disease progression, time from first cycle of olaparib to the first cycle of chemotherapy for the first and second relapse / progression, overall survival) and safety. Median follow up time was 27 months. Results: all patients were Brca mutated, with a 75% predominance of Brca1 mutation. the median platinum-free interval was 13 months. Most patients were treated after the first relapse (64%) with a three-weekly TC protocol (68%). olaparib maintenance therapy provided clinical control rate in 43% of cases. the median progression free survival was 24 months. Discontinuation of olaparib treatment was reported due to disease progression in 16 patients. the median time to first subsequent chemotherapy was 31 months and time to second subsequent chemotherapy was 38 months. The tolerabil ity of olaparib was good and the side effects were low intensity. The median overall survival is not reached. Conclusion: this retrospective analysis of patients with platinum-sensitive, Brca-mutated, recurrent ovarian cancer showed that the treatment outcomes, ie efficacy and tolerability of olaparib after platinum-based chemotherapy in everyday clinical practice, are comparable to those observed in clinical trials with olaparib in the same indications. ous lines of chemotherapy, ie number of previous relapses, response to chemotherapy and plati-num-free interval before olaparib. We analyzed efficacy of olaparib treatment. Disease response to treatment was monitored by the recist (re-sponse evaluation criteria in solid tumors) sys-tem. Response to therapy is defined as a complete response (cr) or complete disappearance of the tumor, partial response (partial response - pr), stable disease (stable Disease - sD) or progression of the disease (progressive Disease - pD). overall survival (OS) is defined by the period from dis ease diagnosis to death from a tumor or from some other cause. progression-free survival (pfs) is defined as the period from the diagnosis of ovarian, fallopian tube, and peritoneal cancer to disease progression, disease recurrence, and/or patient death. TFST (Time to First Subsequent Therapy) is defined as the period from the start of olaparib treatment to the start (chemo)therapy for the first relapse/progression. TSST (Time to Sec ond Subsequent Therapy) is defined as the period from the start of olaparib treatment to the start (chemo)","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43159367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-12DOI: 10.20471/lo.2022.50.01.08
Vitorio Perić, Helga Sertić-Milić, Tomica Bratić, Mirta Zekan-Vučetić, N. Leder, Thomas Ferenc, V. Vidjak
{"title":"Errata corrige: Significance of interventional radiology in liver transplantation","authors":"Vitorio Perić, Helga Sertić-Milić, Tomica Bratić, Mirta Zekan-Vučetić, N. Leder, Thomas Ferenc, V. Vidjak","doi":"10.20471/lo.2022.50.01.08","DOIUrl":"https://doi.org/10.20471/lo.2022.50.01.08","url":null,"abstract":"","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42227624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-12DOI: 10.20471/lo.2022.50.01.02
Rajni Verma, Gourav Kumar Jain, A. Chougule
Summary Introduction: the study was designed to dosimetrically compare the treatment planning optimization techniques to analyze the equivalence of co-60 and ir-192 HDr Brachytherapy sources. further, the present study planned to analyze the equivalence on the basis of technical, logistical and clinical aspects for both the sources. Methods: Thirty-two patients with confirmed diagnosis of carcinoma cervix were included in the study. Comparative treatment plans were made for three different treatment planning optimization techniques for both the sources Co-60 and ir-192 i.e. (a) plans with prescription on point a (Manchester system) with identical dwell position, (b) plans with inverse planning and (c) plans with prescription on Hr-ctV with manual optimization. treatment plans were evaluated on the basis of clinical parameters Hr-ctV V200%, V150%, V100%, D95%, D50%, D2cc Bladder, D2cc rectum and point dose on icrU rectum and Bladder reference point. Results: For the plans with prescription on Point A with identical dwell position, the average percentage difference were found Hr-ctV V200% (6.3%), V150% (5.1%), V100% (1.8%), D2cc rectum (2.3%) and icrU rectum reference point (2.1%) and all these parameters were statistically significant for both the sources. For the Plans with inverse planning opti -mization, these parameters were found significant with average percentage difference HR-CTV V200% (6.1%), V150% (4.9%), D50% (2.1%) and icrU rectum reference point (2.3%). for the plans with dose prescription on Hr-ctV and manual optimization, most of the average percentage differences were found non-significant and clinical parameters were ob served clinically comparable to each other for both the sources. further, it was also observed that on an average ir-192 source required only 42% of the treatment time required by co-60 for the same treatment plan delivery. Conclusion: among all the three planning techniques, the planning technique with prescription on Hr-ctV & manual optimization was found to have comparable clinical quality for both the sources. this analysis revealed that geometry of source placement can overcome the differences in individual source characteristics.
{"title":"Dosimetric analysis of treatment planning optimization techniques for CO-60 and IR-192 HDR brachytherapy sources in carcinoma cervix patients","authors":"Rajni Verma, Gourav Kumar Jain, A. Chougule","doi":"10.20471/lo.2022.50.01.02","DOIUrl":"https://doi.org/10.20471/lo.2022.50.01.02","url":null,"abstract":"Summary Introduction: the study was designed to dosimetrically compare the treatment planning optimization techniques to analyze the equivalence of co-60 and ir-192 HDr Brachytherapy sources. further, the present study planned to analyze the equivalence on the basis of technical, logistical and clinical aspects for both the sources. Methods: Thirty-two patients with confirmed diagnosis of carcinoma cervix were included in the study. Comparative treatment plans were made for three different treatment planning optimization techniques for both the sources Co-60 and ir-192 i.e. (a) plans with prescription on point a (Manchester system) with identical dwell position, (b) plans with inverse planning and (c) plans with prescription on Hr-ctV with manual optimization. treatment plans were evaluated on the basis of clinical parameters Hr-ctV V200%, V150%, V100%, D95%, D50%, D2cc Bladder, D2cc rectum and point dose on icrU rectum and Bladder reference point. Results: For the plans with prescription on Point A with identical dwell position, the average percentage difference were found Hr-ctV V200% (6.3%), V150% (5.1%), V100% (1.8%), D2cc rectum (2.3%) and icrU rectum reference point (2.1%) and all these parameters were statistically significant for both the sources. For the Plans with inverse planning opti -mization, these parameters were found significant with average percentage difference HR-CTV V200% (6.1%), V150% (4.9%), D50% (2.1%) and icrU rectum reference point (2.3%). for the plans with dose prescription on Hr-ctV and manual optimization, most of the average percentage differences were found non-significant and clinical parameters were ob served clinically comparable to each other for both the sources. further, it was also observed that on an average ir-192 source required only 42% of the treatment time required by co-60 for the same treatment plan delivery. Conclusion: among all the three planning techniques, the planning technique with prescription on Hr-ctV & manual optimization was found to have comparable clinical quality for both the sources. this analysis revealed that geometry of source placement can overcome the differences in individual source characteristics.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41981203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-12DOI: 10.20471/lo.2022.50.01.06
Katarina Antunac, L. Beketić-Orešković
The aim of adjuvant radiotherapy in patients with breast cancer is to reduce the risk of disease recurrence; both local and systemic. It also contributes to better overall survival. However, that effect is not consistent across all subgroups of patients. Bearing in mind radiotherapy’s side effects, it is crucial to define patients in which radiotherapy effect on the control of the disease is so low that it can be safely omitted. In general, those would be patients age 70 years or older after breast conserving surgery with hormonal receptor positive tumors, which are smaller than 2 cm (T1) and with uninvolved axillary lymph nodes (N0). It is a matter of discussion whether the same can be applied on HER2 + tumors, on tumors size up to 3 or even 4 cm, or in patients older than 65 or even older than 60 years. Upon mastectomy, radiation should be omitted in patients with tumors lesser than 5 cm and with uninvolved lymph nodes (pT1-2N0 stage). In case cancer treatment started with neoadjuvant systemic therapy, radiotherapy is always indicated after breast conserving surgery, but after mastectomy in clinically or patohistologicaly positive lymph nodes (tumor stage cN+ or ypN+). Pathological response of the tumor on given systemic treatment should not be the major factor determining the decision about indication for radiotherapy.
{"title":"Breast cancer adjuvant radiotherapy - when can it be omitted?","authors":"Katarina Antunac, L. Beketić-Orešković","doi":"10.20471/lo.2022.50.01.06","DOIUrl":"https://doi.org/10.20471/lo.2022.50.01.06","url":null,"abstract":"The aim of adjuvant radiotherapy in patients with breast cancer is to reduce the risk of disease recurrence; both local and systemic. It also contributes to better overall survival. However, that effect is not consistent across all subgroups of patients. Bearing in mind radiotherapy’s side effects, it is crucial to define patients in which radiotherapy effect on the control of the disease is so low that it can be safely omitted. In general, those would be patients age 70 years or older after breast conserving surgery with hormonal receptor positive tumors, which are smaller than 2 cm (T1) and with uninvolved axillary lymph nodes (N0). It is a matter of discussion whether the same can be applied on HER2 + tumors, on tumors size up to 3 or even 4 cm, or in patients older than 65 or even older than 60 years. Upon mastectomy, radiation should be omitted in patients with tumors lesser than 5 cm and with uninvolved lymph nodes (pT1-2N0 stage). In case cancer treatment started with neoadjuvant systemic therapy, radiotherapy is always indicated after breast conserving surgery, but after mastectomy in clinically or patohistologicaly positive lymph nodes (tumor stage cN+ or ypN+). Pathological response of the tumor on given systemic treatment should not be the major factor determining the decision about indication for radiotherapy.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45336707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-12DOI: 10.20471/lo.2022.50.01.05
Tomica Bratić, Mirta Zekan-Vučetić, Filip Brkić, Vittorio Perić, Maja Grubelić-Crnčević, Gordana Lovrečić-Prpić, Saša Schmidt
Clinical trials prior to licensing of COVID-19 vaccines collected key information on effectiveness and safety in general population. During rollout of COVID 19 vaccines, larger and diverse populations is vaccinated. Certain groups, e.g. immunocompromised patients or pregnant women, have not been included in pivotal clinical trials or number of patients included was small. Only approximately 4 percent of the patients enrolled in the phase III trial of Pfizer COVID-19 vaccine had a malignancy of any type, and these patients were not analyzed separately to assess vaccine efficacy;patients with cancer were not enrolled on the Moderna COVID-19 vaccine trial. In the Janssen COVID-19 vaccine phase III trial, only 0.5 percent of patients had cancer. Licensure of a vaccine that is rolled out to a large population in a short time requires not only regular spontaneous reporting but also cohort event monitoring to obtain more in-depth information on the safety of the vaccines. A large-scale cohort event monitoring system is very useful for newly introduced vaccines or for new target groups, in addition to existing spontaneous reporting systems and healthcare database studies (i.e. secondary data), as it is complementary to these systems in several ways. It generates more comprehensive safety data, e.g. on disease course and impact of the adverse events. Moreover, in contrast to spontaneously reported data, the denominator of the studied cohort is known (in real time) so that adverse drug reactions frequencies can be calculated. Therefore, European medicines agency stared study Cohort event monitoring to assess safety of COVID-19 vaccines using patient reported event in several European countries including Croatia to collect more data especially in immunocompromised patient, pregnant woman and patients with allergy in medical history. In Croatia all vaccinated adults can be included up to 6 days after the first or the third dose (more info: http://www.halmed.hr). Clinical Guidances suggest that all individuals with active or prior cancer who are eligible for vaccination according to local allocation priorities be fully vaccinated to prevent SARS-CoV-2 infection. Immunocompromised patients may have attenuated immunogenicity to the COVID vaccines, but vaccination is still recommended in immunocompromised populations. For individuals undergoing hematopoietic cell transplantation (HCT) or cellular therapies such as chimeric antigen receptor (CAR)-T-cell therapy, clinical guidances usually suggest waiting at least three months for vaccination, if possible. Given the potential for a blunted immune response to vaccination, it is important to counsel immunocompromised patients on maintaining personal protective measures despite vaccination.
{"title":"Vesical imaging reporting and data system (VI-RADS), a new modality in bladder cancer treatment","authors":"Tomica Bratić, Mirta Zekan-Vučetić, Filip Brkić, Vittorio Perić, Maja Grubelić-Crnčević, Gordana Lovrečić-Prpić, Saša Schmidt","doi":"10.20471/lo.2022.50.01.05","DOIUrl":"https://doi.org/10.20471/lo.2022.50.01.05","url":null,"abstract":"Clinical trials prior to licensing of COVID-19 vaccines collected key information on effectiveness and safety in general population. During rollout of COVID 19 vaccines, larger and diverse populations is vaccinated. Certain groups, e.g. immunocompromised patients or pregnant women, have not been included in pivotal clinical trials or number of patients included was small. Only approximately 4 percent of the patients enrolled in the phase III trial of Pfizer COVID-19 vaccine had a malignancy of any type, and these patients were not analyzed separately to assess vaccine efficacy;patients with cancer were not enrolled on the Moderna COVID-19 vaccine trial. In the Janssen COVID-19 vaccine phase III trial, only 0.5 percent of patients had cancer. Licensure of a vaccine that is rolled out to a large population in a short time requires not only regular spontaneous reporting but also cohort event monitoring to obtain more in-depth information on the safety of the vaccines. A large-scale cohort event monitoring system is very useful for newly introduced vaccines or for new target groups, in addition to existing spontaneous reporting systems and healthcare database studies (i.e. secondary data), as it is complementary to these systems in several ways. It generates more comprehensive safety data, e.g. on disease course and impact of the adverse events. Moreover, in contrast to spontaneously reported data, the denominator of the studied cohort is known (in real time) so that adverse drug reactions frequencies can be calculated. Therefore, European medicines agency stared study Cohort event monitoring to assess safety of COVID-19 vaccines using patient reported event in several European countries including Croatia to collect more data especially in immunocompromised patient, pregnant woman and patients with allergy in medical history. In Croatia all vaccinated adults can be included up to 6 days after the first or the third dose (more info: http://www.halmed.hr). Clinical Guidances suggest that all individuals with active or prior cancer who are eligible for vaccination according to local allocation priorities be fully vaccinated to prevent SARS-CoV-2 infection. Immunocompromised patients may have attenuated immunogenicity to the COVID vaccines, but vaccination is still recommended in immunocompromised populations. For individuals undergoing hematopoietic cell transplantation (HCT) or cellular therapies such as chimeric antigen receptor (CAR)-T-cell therapy, clinical guidances usually suggest waiting at least three months for vaccination, if possible. Given the potential for a blunted immune response to vaccination, it is important to counsel immunocompromised patients on maintaining personal protective measures despite vaccination.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43444183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-12DOI: 10.20471/lo.2022.50.01.01
I. Milas
{"title":"Fifty years of the journal Libri Oncologici","authors":"I. Milas","doi":"10.20471/lo.2022.50.01.01","DOIUrl":"https://doi.org/10.20471/lo.2022.50.01.01","url":null,"abstract":"","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42508402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-12DOI: 10.20471/lo.2022.50.01.03
Franjo Stručić, V. Rajevac, Katarina Antunac, Meliha Solak-Mekić, F. Cmrečak, L. Beketić-Orešković
Summary prostate cancer has the highest incidence in male population in croatia and radiotherapy has been used as a treatment choice for decades. Volumetric modulated arc therapy (VMat) is a newer radiotherapy technique used at our department for the last year. in our study we performed the estimation of quality improvement achieved by VMat radiation technique in comparison to 3D crt for prostate bed irradiation. conformity index (ci) and dose delivered to organs at risk (oars) have been observed. VMAT was superior in achieving more conformal dose. This method was also significantly better at sparing surrounding oars, especially rectum and femoral heads.
{"title":"Comparison of volumetric arc modulated radiotherapy and 3D conformal radiotherapy in prostate bed irradiation","authors":"Franjo Stručić, V. Rajevac, Katarina Antunac, Meliha Solak-Mekić, F. Cmrečak, L. Beketić-Orešković","doi":"10.20471/lo.2022.50.01.03","DOIUrl":"https://doi.org/10.20471/lo.2022.50.01.03","url":null,"abstract":"Summary prostate cancer has the highest incidence in male population in croatia and radiotherapy has been used as a treatment choice for decades. Volumetric modulated arc therapy (VMat) is a newer radiotherapy technique used at our department for the last year. in our study we performed the estimation of quality improvement achieved by VMat radiation technique in comparison to 3D crt for prostate bed irradiation. conformity index (ci) and dose delivered to organs at risk (oars) have been observed. VMAT was superior in achieving more conformal dose. This method was also significantly better at sparing surrounding oars, especially rectum and femoral heads.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42809696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-22DOI: 10.20471/lo.2021.49.02-03.07
Ana Car-Peterko, M. Avirović, P. Valković-Zujić, K. Rajković-Molek, ingrid Belac-Lovasić, F. Lovasić
Summary Background: in modern breast cancer management, slnB is a standard of care. for the patients with limited sentinel lymph node involvement in the upfront surgery setting, ALND can be safely omitted. However, for any sentinel node metastasis detected following neoadjuvant systemic treatment (nst), alnD is still considered a mandatory procedure. Patients and methods: Present retrospective analysis has included all breast cancer patients submitted to surgery follow ing nst in clinical Hospital centre (cHc) rijeka in the period from 2017 till 2020. Results: slnB was performed in 151 of 222 consecutive patients, and sentinel node metastasis was detected in 49 cases. the risk of non-sentinel lymph node involvement in sentinel node-positive patients was 34.7%, but exclusively for cases with macro-metastatic disease detected in the sentinel node. in addition, for the patients diagnosed with clinically uninvolved axilla, the risk of ypn2-3 status was only 2.8%. Conclusions: alnD following nst is overtreatment in 65.3% of sentinel node-positive patients. axillary irradiation with the omission of alnD should be considered for the sentinel-positive patients with only micro-metastatic disease detected in the sentinel node following neoadjuvant chemotherapy, as well as for those with low volume macro-metastatic disease, diagnosed with the uninvolved axilla.
{"title":"Axillary lymph node dissection could be omitted in the breast cancer patients with a limited sentinel lymph node involvement following neoadjuvant systemic treatment","authors":"Ana Car-Peterko, M. Avirović, P. Valković-Zujić, K. Rajković-Molek, ingrid Belac-Lovasić, F. Lovasić","doi":"10.20471/lo.2021.49.02-03.07","DOIUrl":"https://doi.org/10.20471/lo.2021.49.02-03.07","url":null,"abstract":"Summary Background: in modern breast cancer management, slnB is a standard of care. for the patients with limited sentinel lymph node involvement in the upfront surgery setting, ALND can be safely omitted. However, for any sentinel node metastasis detected following neoadjuvant systemic treatment (nst), alnD is still considered a mandatory procedure. Patients and methods: Present retrospective analysis has included all breast cancer patients submitted to surgery follow ing nst in clinical Hospital centre (cHc) rijeka in the period from 2017 till 2020. Results: slnB was performed in 151 of 222 consecutive patients, and sentinel node metastasis was detected in 49 cases. the risk of non-sentinel lymph node involvement in sentinel node-positive patients was 34.7%, but exclusively for cases with macro-metastatic disease detected in the sentinel node. in addition, for the patients diagnosed with clinically uninvolved axilla, the risk of ypn2-3 status was only 2.8%. Conclusions: alnD following nst is overtreatment in 65.3% of sentinel node-positive patients. axillary irradiation with the omission of alnD should be considered for the sentinel-positive patients with only micro-metastatic disease detected in the sentinel node following neoadjuvant chemotherapy, as well as for those with low volume macro-metastatic disease, diagnosed with the uninvolved axilla.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47403988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-22DOI: 10.20471/lo.2021.49.02-03.10
Lana Jajac-Bručić, F. Grubišić-Čabo, Josipa Jović-Zlatović, I. Krečak
In randomized clinical trials, trifluridine / tipiracil (TT) demonstrated beneficial effects on progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC). The aim of this unicentric study was to evaluate the efficacy and safety of TT in patients with refractory mCRC in everyday clinical practice. Treatment outcomes of 20 patients were retrospectively analyzed. The median OS was 6.25 months (range 1-18) and the median PFS was 3 months (range 2–13). The most common (80%) side effect of TT was neutropenia and 35% of patients had neutropenia grades 3 of 4; however, only two patients (10%) had neutropenic fever and no deaths were attributable to neutropenia. In conclusion, treatment outcomes in this real-life study seem comparable to those from randomized clinical trials.
{"title":"Efficacy and tolerability of trifluridine/tipiracil in patients with refractory metastatic colorectal cancer at the general hospital of Šibenik-Knin country","authors":"Lana Jajac-Bručić, F. Grubišić-Čabo, Josipa Jović-Zlatović, I. Krečak","doi":"10.20471/lo.2021.49.02-03.10","DOIUrl":"https://doi.org/10.20471/lo.2021.49.02-03.10","url":null,"abstract":"In randomized clinical trials, trifluridine / tipiracil (TT) demonstrated beneficial effects on progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC). The aim of this unicentric study was to evaluate the efficacy and safety of TT in patients with refractory mCRC in everyday clinical practice. Treatment outcomes of 20 patients were retrospectively analyzed. The median OS was 6.25 months (range 1-18) and the median PFS was 3 months (range 2–13). The most common (80%) side effect of TT was neutropenia and 35% of patients had neutropenia grades 3 of 4; however, only two patients (10%) had neutropenic fever and no deaths were attributable to neutropenia. In conclusion, treatment outcomes in this real-life study seem comparable to those from randomized clinical trials.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44903976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：